31.8.2016

To:
Unit B4 "Medical products – Quality, Safety and Innovation"
SANTE-B4-GL-IMP-AMP@ec.europa.eu
European Commission
F101 08/058
B-1049 Brussels (Belgium)

# Submission of comments on **Definition of Investigational Medicinal Products (IMPs) and use of Auxiliary Medicinal Products (AMPs)**

# Comments from:

# Name of organisation or individual

### **EuropaBio - the European Association for Bioindustries**

Avenue de l'Armée 6 | B-1040 Brussels www.europabio.org

Business association registered in EU Transparency Register. Identification number in the register: 1298286943-59

Contact: Riccardo Mezzasalma, Healthcare Biotechnology Manager

r.mezzasalma@europabio.org

## 1. General comments

# General comment (if any)

EuropaBio welcomes the opportunity to respond to this public consultation, which is touching on a topic of particular interest to our members.

EuropaBio has had sight of the response to this consultation by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and supports the comments submitted by EFPIA.